Diagnostics Development: A New Approach
We’re creating large-scale, blood-based molecular diagnostics that leverage advances in proteomics and genomics to detect disease at its earliest stage. The company was co-founded by Dr. Lee Hood in 2009 to develop diagnostics and measurement technologies capable of monitoring hundreds of biomarkers simultaneously, for earlier detection and more accurate management of complex diseases like lung cancer and Alzheimer’s disease.
A Systems Biology View
Diagnostics development at Indi is conceptually based on a systems biology view of disease – one where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules. By aiming to understand the whole system – and make sense out of a wealth of new genomics and proteomic information – we are creating diagnostics capable of detecting disease earlier, with greater precision.
Center of a Diagnostics Ecosystem
Indi is at the center of a unique network of scientists, partners and investors who share a vision for molecular diagnostics. The organization’s work is based on intellectual property developed by our board members at the Institute of Systems Biology (ISB) and Caltech.
In 2009, Indi became the first commercial enterprise to arise from a $100 million research collaboration between ISB and the University of Luxembourg; the company has ongoing access to the research from this continuing partnership.
Indi’ investors include InterWest Partners, The Wellcome Trust and BioTechCube Luxembourg.
“For years diagnostics development has meant investigating just a few biomarkers at a time. Now Indi has brought together the technology, data and people to create diagnostics that are two orders of magnitude larger – to gain a systems view of health and disease.”